Fight Continues Against Trump Administration Changes To 340B Drug Discount Program

TL;DR

For listenersOffer from Amazon

Turn quiet afternoons into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

The American Hospital Association, four safety-net hospitals and the Maine Hospital Association have sued the Trump administration over a planned change to the 340B drug discount program. The system, scheduled to begin January 1, 2027, would require hospitals to pay regular prices upfront and seek rebates later; the plaintiffs say it could add more than $1 billion in annual administrative costs. The court is expected to rule before the change is due to take effect.

The American Hospital Association, four safety-net hospitals and the Maine Hospital Association have sued the Trump administration to stop a planned change to the 340B drug discount program, arguing that requiring hospitals to pay full prices upfront and claim rebates later could strain finances and divert resources from care. The new system is scheduled to take effect January 1, 2027, and the court is expected to decide the challenge before then.

Under the current arrangement, eligible hospitals receive discounted prices when they buy medicines. The report describes typical discounts as about 13% for generic drugs and 23% for brand-name drugs. Under the administration’s planned rebate model, hospitals would instead pay the regular price first and submit a claim after dispensing the drug. The lawsuit asks the court to cancel the change and retain the existing system.

The AHA says estimates suggest the change could impose more than $1 billion in annual administrative costs on hospitals. The association also argues that higher upfront spending and new paperwork would redirect money and staff time from patient services. These are the plaintiffs’ estimates and arguments; the supplied report does not provide an independent calculation of the projected costs.

The Health Resources and Services Administration, which runs the program, reported that covered entities spent $100 billion on 340B drugs in 2025, up from $81.4 billion in 2024 and $66.3 billion in 2023. Those figures measure drug spending through the program, not the amount hospitals saved or how much they spent on patient services.

How Rebate Timing Could Affect Hospitals

The dispute concerns when hospitals receive the benefit of the discount. Under the proposed approach, hospitals would have to finance the full purchase price before seeking reimbursement, creating a potential cash-flow burden as well as additional claims work. The AHA and hospital plaintiffs say that pressure could be especially difficult for rural and safety-net providers, which rely on program savings to support services for low-income communities.

The policy has consequences beyond hospital accounting because 340B participants say savings help sustain access to medicines and services including behavioral health and oncology care. Those effects are asserted by program participants; the supplied material does not establish how any particular hospital would change its services if the rebate model proceeds. The outcome of the lawsuit will determine whether the scheduled change can go ahead, and may affect how hospitals plan purchases and budgets for 2027.

A Dispute Over 340B’s Scale

The 340B program provides discounted medicines to eligible health care organizations serving low-income and other underserved patients. The policy has been contested by hospitals and pharmaceutical companies over the program’s scale, oversight and use of savings. Drug manufacturers argue that some hospitals benefit excessively and that there are insufficient safeguards for how savings are used.

PhRMA, the drug industry trade group, says hospitals can buy medicines at very low prices and mark them up, and describes the program as imposing costs on patients, employers and taxpayers. It also cites a figure of $142 billion in hospital profits on medicines. That is the trade group’s claim; the supplied report does not provide the underlying methodology or an independent verification. Hospital advocates, by contrast, say spending growth reflects factors including more outpatient care and the use of expensive specialty drugs.

This is not the administration’s first attempt to introduce a rebate-based model. A similar effort announced the previous year was blocked by courts, according to the report. Maureen Testoni, head of 340B Health, said the current plan repeats that approach and could face another legal challenge. The pending case is about the new policy and its legal basis; the earlier court action does not by itself determine how this case will be decided.

“The proposed shift from upfront 340B discounts to a rebate-based system would place significant financial pressure and administrative burdens on hospitals and clinics that rely on 340B savings to support essential patient care services.”

— Guy Hudson, president and CEO of Northern Light Health

Costs and Court Ruling Still Pending

The court has not yet ruled on the hospitals’ request, and the supplied report does not say whether the administration has filed a response or announced any change to the January start date. The briefing period is expected to end in mid-November; the judge will then decide whether oral arguments are needed. A ruling is expected before the program is scheduled to change, but the exact date and outcome are unknown.

The projected administrative burden of more than $1 billion annually comes from estimates cited by the AHA. The material does not give a detailed methodology or establish what costs individual hospitals would face. Nor does it resolve the competing claims about how hospitals use 340B savings, the extent of any markups, or whether the rebate structure would affect patient access at particular facilities.

Court Review Before January Start

The parties are due to complete briefing in mid-November 2026. After that, the judge will decide whether to hear oral arguments and consider whether the administration can implement the rebate model. The report says a decision is expected before January 1, 2027, when the change is scheduled to begin.

Until the court rules or the administration changes course, the planned start date remains the relevant deadline. Hospitals, drug companies and patients will be watching for the decision because it will determine whether eligible providers continue receiving discounts at purchase or must pay upfront and pursue rebates afterward.

Key Questions

What change to the 340B program are hospitals challenging?

The planned system would replace upfront discounts with a process in which hospitals pay regular prices for drugs and seek rebates after dispensing them.

Who filed the lawsuit?

The plaintiffs are the American Hospital Association, four safety-net hospitals and the Maine Hospital Association. They are asking the court to block the change and keep the current arrangement.

When is the rebate system scheduled to start?

The planned start date is January 1, 2027. The report says a decision in the lawsuit is expected before that date, though the exact ruling date is not known.

How much could the change cost hospitals?

The AHA cites estimates of more than $1 billion in annual administrative costs. That figure is an estimate advanced by the association; the supplied material does not include an independent cost assessment.

What happens next in the case?

Briefing is expected to end in mid-November 2026. The judge will then decide whether oral arguments are needed and is expected to issue a decision before the scheduled January start.

Source: rss